KYPROLIS (Carfilzomib)

What is Kyprolis (Carfilzomib)
Kyprolis is an anti-cancer drug acting as a selective proteasome inhibitor. Chemically it is a tetrapeptide epoxyketone and an analog of epoxomicin.

KYPROLIS

Drug Manufacturer / Marketeer :

M/s Onyx Pharmaceuticals, Inc


Available as:

60MG POWDER.

Indications:
Kyprolis® for injection is approved to treat patients with multiple myeloma who have received at least 2 prior therapies including bortezomib and an immunomodulatory agent and whose disease has progressed on or within 60 days of completion of the last therapy.

Treatment:
For treatment related information, please consult your treating Physician.

How supplied:
Kyprolis for injection is supplied as an individually cartoned as a single use vial containing a dose of 60 mg of carfilzomib as a white to off-white lyophilized cake or powder.

Storage and handling:
Unopened vials should be stored refrigerated (2° to 8° degrees C)

How do we source the Drug?
SMIQ Pharma will assist in sourcing the drug through its efficient network, across the globe, and ensure the delivery is prompt. However, a valid prescription from the treating Oncologist is mandatory, with all relevant documents associated with its procurement is also essential.

Company that Manufactures/ Markets:
M/s Onyx Pharmaceuticals, Inc

Assistance Cell in India:
For ONCOLOGY DRUG: KYPROLIS (Carfilzomib) 60MG price.

Contact us @ +91 7678048225 or by email  info@smiqpharma.com.